Search Result

Pathways Recommended:	Antibody-drug Conjugate/ADC Related

Results for "

PSMA inhibitor conjugate

" in MedChemExpress (MCE) Product Catalog:

By Targets:	PSMA (12) Antibody-Drug Conjugates (ADCs) (1) Cytochrome P450 (1) Drug Intermediate (1) Drug Isomer (1) Microtubule/Tubulin (1) PARP (1) Radionuclide-Drug Conjugates (RDCs) (7) Reactive Oxygen Species (ROS) (1)
By Research Areas:	Cancer (12)

Inhibitors & Agonists

Peptides

Targets Recommended: PSMA

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-141860

PSMA-Val-Cit-PAB-MMAE	PSMA Microtubule/Tubulin Reactive Oxygen Species (ROS) Cytochrome P450	Cancer
PSMA-Val-Cit-PAB-MMAE is a small-molecule conjugate targeting *PSMA, with Monomethyl auristatin E (MMAE) (HY-15162) as its cytotoxic payload. PSMA-Val-Cit-PAB-MMAE binds to PSMA, thereby being delivered into PSMA*-expressing prostate cancer cells. Subsequently, the Val-Cit linker is cleaved under the mediation of cathepsin B, releasing active MMAE. PSMA-Val-Cit-PAB-MMAE inhibits CYP3A4 activity (IC₅₀ = 11.2 μM), induces intracellular ROS production and oxidative stress, disrupts the cytoskeleton through microtubule destabilization, and induces prostate cancer cell death. PSMA-Val-Cit-PAB-MMAE can be used in research related to prostate cancer .

HY-147287

Glu-urea-Glu-NHS ester	PSMA Drug Intermediate	Cancer
Glu-urea-Glu-NHS ester is an activated N-hydroxysuccinamide (NHS) ester of Glu-urea-Glu. Glu-urea-Glu-NHS ester can be used for synthesis of small-molecule prostate-specific membrane antigen (PSMA) inhibitors, imaging agents (such as PSMAi-PEG conjugates), and targeted drug delivery vehicles .

HY-114256

EC1169	PSMA	Cancer
EC1169 is a cytotoxic maytansinoid conjugate that specifically binds to prostate-specific membrane antigen (PSMA). EC1169 precisely delivers the maytansinoid B hydrazide payload to *PSMA*-positive cells to exert antitumor activity. EC1169 only inhibits the growth of PSMA-positive cells but has no effect on PSMA-negative cells, and enables complete recovery in mice bearing PSMA-positive tumors. EC1169 exhibits safety with no body weight loss or major organ damage induced. EC1169 is used in studies of prostate cancer and other PSMA-expressing malignancies .

HY-P5292A

HYNIC-iPSMA TFA	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
HYNIC-iPSMA TFA is a ligand for molecular imaging of tumors. Hynic-ipsma consists of two components: HYNIC (6-hydrazinonicotinamide) and iPSMA (Inhibitor of Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules. iPSMA is a specific inhibitor used to inhibit prostate-specific membrane antigen (PSMA). 68GA-labeled iPSMA has been used to detect prostate cancer by PET imaging. The further 99mTc-EDDA/HYNIC-iPSMA TFA has excellent specificity and sensitivity . HYNIC-iPSMA TFA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-164575

NH2-NODAGA	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
NH2-NODAGA is an amino-modified NODAGA-type bifunctional chelator, specifically designed for amidation coupling with targeting ligands via squaric acid (SA), followed by coordination with radionuclides (e.g., ⁶⁸Ga, ¹⁷⁷Lu). NH2-NODAGA can be coupled with diethyl squarate to form a PSMA inhibitor conjugate, which is used in prostate cancer research .

HY-P5292

HYNIC-iPSMA	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
HYNIC-iPSMA is a ligand for molecular imaging of tumors. Hynic-ipsma consists of two components: HYNIC (6-hydrazinonicotinamide) and iPSMA (Inhibitor of Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules. iPSMA is a specific inhibitor used to inhibit prostate-specific membrane antigen (PSMA). 68GA-labeled iPSMA has been used to detect prostate cancer by PET imaging. The further 99mTc-EDDA/HYNIC-iPSMA has excellent specificity and sensitivity . HYNIC-iPSMA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-158266

DOTA-PSMA-EB-01 LNC1003	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
DOTA-PSMA-EB-01 (Compound LNC1003) is a specific inhibitor of *PSMA* (IC₅₀= 10.77 nM).DOTA-PSMA-EB-01 enhances the uptake and retention time of ¹⁷⁷Lu in tumors . DOTA-PSMA-EB-01 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-169336

CQ-16	PARP PSMA	Cancer
CQ-16 is an orally active small molecule drug conjugate (SMDC) targeting prostate-specific membrane antigen (PSMA). CQ-16 exhibits highly selective antiproliferative activity between *PSMA*-positive and *PSMA*-negative prostate cells. In addition, CQ-16 also has PARP inhibitory activity (IC₅₀=1 nM). (Pink: PSMA Ligand (HY-139840); Black: Linker (HY-W037980); Blue: PARP Inhibitor (HY-10162))

HY-185729

MEDI3726 ADCT-401	Antibody-Drug Conjugates (ADCs) PSMA	Cancer
MEDI3726 (ADCT-401) is a prostate-specific membrane antigen (PSMA)-targeting antibody-drug conjugate (ADC), composed of LP Tesirine (HY-128952) and antibody J591 (HY-P991359). MEDI3726 binds *PSMA’s extracellular domain, triggers endocytosis, undergoes lysosomal degradation to release a pyrrolobenzodiazepine warhead. MEDI3726 induces DNA crosslinking, DNA damage, cell death, cytotoxicity, and inhibits* tumor growth in mouse xenograft models. MEDI3726 undergoes in vivo catabolism primarily via heavy-light chain dissociation, with minimal warhead deconjugation. MEDI3726 can be used for the research of metastatic castration-resistant prostate cancer and prostate cancers .

HY-164575B

NH2-NODAGA hydrochloride	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
NH2-NODAGA hydrochloride is an amino-modified NODAGA-type bifunctional chelator, specifically designed for amidation coupling with targeting ligands via squaric acid (SA), followed by coordination with radionuclides (e.g., ⁶⁸Ga, ¹⁷⁷Lu). NH2-NODAGA hydrochloride can be coupled with diethyl squarate to form a PSMA inhibitor conjugate, which is used in prostate cancer research .

HY-164575A

NH2-NODAGA TFA	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
NH2-NODAGA TFA is an amino-modified NODAGA-type bifunctional chelator, specifically designed for amidation coupling with targeting ligands via squaric acid (SA), followed by coordination with radionuclides (e.g., ⁶⁸Ga, ¹⁷⁷Lu). NH2-NODAGA TFA can be coupled with diethyl squarate to form a PSMA inhibitor conjugate, which is used in prostate cancer research .

HY-164575C

(S)-NH2-NODAGA hydrochloride	Drug Isomer Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
(S)-NH2-NODAGA hydrochloride is the S isomer of NH2-NODAGA hydrochloride (HY-164575B). NH2-NODAGA hydrochloride is an amino-modified NODAGA-type bifunctional chelator, specifically designed for amidation coupling with targeting ligands via squaric acid (SA), followed by coordination with radionuclides (e.g., ⁶⁸Ga, ¹⁷⁷Lu). NH2-NODAGA hydrochloride can be coupled with diethyl squarate to form a PSMA inhibitor conjugate, which is used in prostate cancer research.

Cat. No.	Product Name	Target	Research Area

HY-P5292A

HYNIC-iPSMA TFA	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
HYNIC-iPSMA TFA is a ligand for molecular imaging of tumors. Hynic-ipsma consists of two components: HYNIC (6-hydrazinonicotinamide) and iPSMA (Inhibitor of Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules. iPSMA is a specific inhibitor used to inhibit prostate-specific membrane antigen (PSMA). 68GA-labeled iPSMA has been used to detect prostate cancer by PET imaging. The further 99mTc-EDDA/HYNIC-iPSMA TFA has excellent specificity and sensitivity . HYNIC-iPSMA TFA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P5292

HYNIC-iPSMA	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
HYNIC-iPSMA is a ligand for molecular imaging of tumors. Hynic-ipsma consists of two components: HYNIC (6-hydrazinonicotinamide) and iPSMA (Inhibitor of Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules. iPSMA is a specific inhibitor used to inhibit prostate-specific membrane antigen (PSMA). 68GA-labeled iPSMA has been used to detect prostate cancer by PET imaging. The further 99mTc-EDDA/HYNIC-iPSMA has excellent specificity and sensitivity . HYNIC-iPSMA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-158266

DOTA-PSMA-EB-01 LNC1003	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
DOTA-PSMA-EB-01 (Compound LNC1003) is a specific inhibitor of *PSMA* (IC₅₀= 10.77 nM).DOTA-PSMA-EB-01 enhances the uptake and retention time of ¹⁷⁷Lu in tumors . DOTA-PSMA-EB-01 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
Email *

	Sorry, but the email address you supplied was invalid.